Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center,
Kingsville, Texas, USA
Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=158). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Cancer, one of the leading causes of death worldwide is characterized by three phases viz initiation, development and progression of a tumor mass. In all these phases, tumor microenvironment islargely orchestrated by inflammatory cells. These cells become indispensable participant in the neoplastic process, nurturing proliferation, survival, and migration. Inflammation is a host protective response and deregulated inflammatory response is a critical component of tumor progression. Prolonged inflammation otherwise known as chronic inflammation promotes cancer progression while an acute inflammation contributes to cancer regression. Epidemiological evidence points to a connection between inflammation and a predisposition for the development of cancer. Various potential molecular and cellular mediators such as cytokines, chemokines, oncogenes, enzymes, transcription factors, and immune cells drive the transition of chronic inflammation to cancer. These molecular mediators are critical cornerstones between inflammation and cancer, and their activation and/or deactivation are influenced by both environmental and hereditary factors. Protein kinases are one among those molecular mediators that have been known as valuable molecular target and play a crucial role in signal transduction, cellular proliferation, differentiation and other regulatory mechanisms associated with inflammation mediated cancer cell signaling processes. Understanding of these concepts helped in redesigning new therapeutic strategies against molecular mediators to assist in cancer treatment and disease management.
The goal of this special issue is to improve our understanding on the nature of deregulated cell signaling pathways and associated key signaling molecules that are involved in inflammation mediated cancers of different origin. Additionally, this special issue also discusses on how these new discoveries outline the need to redesign the targeted cancer therapeutic strategies to specifically target inflammation, and cancer. Overall, this information would provide an important beginning to the broader efforts of developing new therapeutic avenues. We would like to include reviews, mini reviews and original articles in our special issue which will be a nice and intellectual treat to our readers.Aims and Scope:
1. Cell signaling in inflammation associated cancer
Role of molecular and cellular mediators in inflammation and cancer Role of protein kinases in inflammation and cancer
2. Role of key upstream and downstream players of tyrosine kinases in inflammation and cancer
Tyrosine kinases as “molecular targets” for cancer therapy Therapeutic protein tyrosine kinase inhibitors for treatment of inflammation mediated cancer.
3. Tyrosine kinase inhibitor resistance in chronic inflammation and inflammation mediated cancer.